Skip to main content

Table 1 Demographic and clinical characteristics of the patients in the cohort and stratified by the occurrence of specific opportunistic illnesses

From: Predictors of opportunistic illnesses incidence in post combination antiretroviral therapy era in an urban cohort from Rio de Janeiro, Brazil

 

Tuberculosis

Esophageal candidiasis

Cerebral toxoplasmosis

PCP

All patientsa

 
 

N = 177

N = 100

N = 70

N = 55

N = 2835

p-value

Incidence rateb (CI 95 %)

15.3 (13.2, 17.7)

8.6 (7.1, 10.5)

6.0 (4.8, 7.6)

4.8 (367, 6.2)

–

<0.001

Age, median (IQR)

35.4 (28.4,41.5)

38.6 (32.6,45)

33.8 (28.1,40.9)

39.1 (29.6,45.1)

35.6 (28.7,42.7)

0.02

 18–29 years (%)

50 (28.2)

15 (15)

21 (30)

13 (23.6)

750 (26.5)

0.05

 30–39 years (%)

67 (37.9)

36 (36)

27 (38.6)

13 (23.6)

1035 (36.5)

 

 40–49 years (%)

46 (26)

34 (34)

16 (22.9)

19 (34.5)

731 (25.8)

 

 50+ years (%)

14 (7.9)

15 (15)

6 (8.6)

10 (18.2)

319 (11.3)

 

Gender-risk

     

0.21

 Women

57 (32.2)

41 (41)

27 (38.6)

11 (20)

930 (32.8)

 

 Heterossexual men

59 (33.3)

27 (27)

23 (32.9)

22 (40)

833 (29.4)

 

 MSM

61 (34.5)

32 (32)

20 (28.6)

22 (40)

1072 (37.8)

 

Race/ethnicity

     

0.12

 White (%)

73 (41.2)

40 (40)

29 (41.4)

32 (58.2)

1415 (49.9)

 

 Non-white (%)

104 (58.8)

60 (60)

41 (58.6)

23 (41.8)

1420 (50.1)

 

Educational level

     

0.03

 0–8 years (%)

117 (66.1)

66 (66)

48 (68.6)

25 (45.5)

1399 (49.3)

 

 9+ years (%)

60 (33.9)

34 (34)

22 (31.4)

30 (54.5)

1436 (50.7)

 

Nadir CD4 T-cell count (cells/mm3)

     

Median (IQR)

107 (48,218)

74.5 (21,188.2)

63.5 (20,159.5)

55 (12,146)

196 (71,311.5)

0.002

 <50 (%)

45 (25.4)

39 (39)

33 (47.1)

25 (45.5)

549 (19.4)

0.03

 50–199 (%)

82 (46.3)

39 (39)

27 (38.6)

22 (40)

898 (31.7)

 

 200–349 (%)

40 (22.6)

17 (17)

8 (11.4)

5 (9.1)

847 (29.9)

 

 350+ (%)

10 (5.6)

5 (5)

2 (2.9)

3 (5.5)

541 (19.1)

 

Opportunistic illness at enrolmment

44 (24.9)

43 (43)

35 (50)

21 (38.2)

211 (7.4)

<0.001

cART use during follow-up (%)

30 (16.9)

10 (10)

12 (17.1)

8 (14.5)

1878 (66.2)

0.43

Time of cART use in yearsc, median (IQR)

1.1 (0.6,2.7)

0.8 (0.4,1.3)

0.6 (0.1,1.6)

1.7 (1.1,2.1)

2.2 (0.9,4.1)

0.32

  1. cART combination antiretroviral therapy, PCP Pneumocystis jiroveci pneumonia, HR, hazard ratio, CI confidence interval, MSM men who have sex with men
  2. aIncludes the entire study population
  3. bPer 1000 person-years
  4. cFor those who used cART before end of follow-up
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us